Chitosan nanoparticles as delivery system for nasal immunisation

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F23%3A10464869" target="_blank" >RIV/00179906:_____/23:10464869 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/60162694:G44__/24:00560277 RIV/00216275:25310/23:39918766

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=2LC9Z6_IS" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=2LC9Z6_IS</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.31482/mmsl.2022.023" target="_blank" >10.31482/mmsl.2022.023</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Chitosan nanoparticles as delivery system for nasal immunisation

Popis výsledku v původním jazyce

Nasal immunisation represents an innovative and perspective route of vaccine administration that provides many benefits compared to the more traditional approaches. Since most infections start on mucosal membranes, the mucosal immunisation provides a rational reason for its application. Mucosal delivery for vaccine administration (for example oral or nasal routes) could stimulate both systemic and mucosal immune responses. However, there are still some limitations that should be solved for a broader utilisation of this approach. There is still the necessity to use strongly immunogenic antigens or appropriate adjuvants for the induction of a strong immune response. The use of nanoparticles in the vaccine development could represent a promising approach for the mucosal vaccine research. Nanoparticles could thus serve as delivery vehicles providing to vaccines their unique properties, such as the antigen stabilisation and protection, serve as an adjuvant and elicit an antigen-specific immune response on the target sites.

Název v anglickém jazyce

Chitosan nanoparticles as delivery system for nasal immunisation

Popis výsledku anglicky

Nasal immunisation represents an innovative and perspective route of vaccine administration that provides many benefits compared to the more traditional approaches. Since most infections start on mucosal membranes, the mucosal immunisation provides a rational reason for its application. Mucosal delivery for vaccine administration (for example oral or nasal routes) could stimulate both systemic and mucosal immune responses. However, there are still some limitations that should be solved for a broader utilisation of this approach. There is still the necessity to use strongly immunogenic antigens or appropriate adjuvants for the induction of a strong immune response. The use of nanoparticles in the vaccine development could represent a promising approach for the mucosal vaccine research. Nanoparticles could thus serve as delivery vehicles providing to vaccines their unique properties, such as the antigen stabilisation and protection, serve as an adjuvant and elicit an antigen-specific immune response on the target sites.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30303 - Infectious Diseases

Projekt

<a href="/cs/project/LTAUSA19003" target="_blank" >LTAUSA19003: Indukce protivirové imunitní odpovědi slizniční vakcinací s užitím nanočástic</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Military Medical Science Letters - Vojenské zdravotnické listy

ISSN

0372-7025

e-ISSN

2571-113X

Svazek periodika

92

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

9

Strana od-do

48-56

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85150370570